Tyra Biosciences

Update in progress

TYRA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on FGFR biology in the United States. It offers SNÅP, a precision medicine platform that guides drug design by generating iterative molecular snapshots to predict genetic changes for oncology and other FGFR3-driven conditions. Its lead candidate, FGFR3, is in trials for metastatic urothelial carcinoma and other solid tumors. TYRA-300 targets skeletal FGFR3-related disorders; TYRA-200 targets intrahepatic cholangiocarcinoma; TYRA-430 targets hepatocellular carcinoma. Founded in 2018, it is headquartered in Carlsbad, California.

Company score

Sentiment: 0.14; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.09; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive